This KIN PE ratio history page last updated 9/22/2021
Period | Price | GAAP | Annualized | PE |
Q2 2021 8/5/2021 | 9.22 | -0.20 | -0.80 | NA | Q1 2021 5/11/2021 | 4.43 | -0.24 | -0.96 | NA | Q4 2020 3/16/2021 | 4.94 | -0.28 | -1.12 | NA | Q3 2020 11/9/2020 | 3.77 | -0.31 | -1.24 | NA | Q2 2020 8/5/2020 | 3.75 | 0.60 | 2.40 | 1.6 | Q1 2020 5/7/2020 | 4.53 | -0.45 | -1.80 | NA | Q4 2019 3/16/2020 | 6.01 | -0.40 | -1.60 | NA | Q3 2019 11/12/2019 | 8.28 | -0.39 | -1.56 | NA | Q2 2019 8/1/2019 | 6.96 | -0.37 | -1.48 | NA | Q1 2019 5/9/2019 | 8.97 | -0.42 | -1.68 | NA | Q4 2018 3/6/2019 | 10.75 | -0.46 | -1.84 | NA | Q3 2018 11/7/2018 | 14.59 | -0.39 | -1.56 | NA | Q2 2018 8/9/2018 | 13.80 | -0.39 | -1.56 | NA | Q1 2018 5/8/2018 | 9.70 | -0.36 | -1.44 | NA | Q4 2017 3/1/2018 | 8.90 | -0.35 | -1.40 | NA | Q3 2017 11/7/2017 | 7.60 | -0.29 | -1.16 | NA | Q2 2017 8/7/2017 | 7.35 | -0.29 | -1.16 | NA | Q1 2017 5/3/2017 | 6.95 | -0.30 | -1.20 | NA | Q4 2016 3/1/2017 | 5.35 | -0.29 | -1.16 | NA | Q3 2016 11/7/2016 | 5.10 | -0.29 | -1.16 | NA | Q2 2016 8/8/2016 | 3.96 | -0.25 | -1.00 | NA | Q1 2016 5/5/2016 | 3.36 | -0.31 | -1.24 | NA | Q4 2015 3/2/2016 | 3.81 | -0.32 | -1.28 | NA | Q3 2015 11/9/2015 | 5.53 | -0.36 | -1.44 | NA | Q2 2015 8/10/2015 | 6.06 | -0.35 | -1.40 | NA | Q1 2015 5/8/2015 | 7.10 | -0.34 | -1.36 | NA | Q4 2014 3/12/2015 | 6.86 | -0.34 | -1.36 | NA | Q3 2014 11/13/2014 | 8.98 | -0.31 | -1.24 | NA | Q2 2014 8/13/2014 | 15.82 | -0.42 | -1.68 | NA | Q1 2014 5/12/2014 | 16.63 | -0.38 | -1.52 | NA |
|
Period | Price | GAAP | TTM | PE |
Q2 2021 8/5/2021 | 9.22 | -0.20 | -1.03 | NA | Q1 2021 5/11/2021 | 4.43 | -0.24 | -0.23 | NA | Q4 2020 3/16/2021 | 4.94 | -0.28 | -0.44 | NA | Q3 2020 11/9/2020 | 3.77 | -0.31 | -0.56 | NA | Q2 2020 8/5/2020 | 3.75 | 0.60 | -0.64 | NA | Q1 2020 5/7/2020 | 4.53 | -0.45 | -1.61 | NA | Q4 2019 3/16/2020 | 6.01 | -0.40 | -1.58 | NA | Q3 2019 11/12/2019 | 8.28 | -0.39 | -1.64 | NA | Q2 2019 8/1/2019 | 6.96 | -0.37 | -1.64 | NA | Q1 2019 5/9/2019 | 8.97 | -0.42 | -1.66 | NA | Q4 2018 3/6/2019 | 10.75 | -0.46 | -1.60 | NA | Q3 2018 11/7/2018 | 14.59 | -0.39 | -1.49 | NA | Q2 2018 8/9/2018 | 13.80 | -0.39 | -1.39 | NA | Q1 2018 5/8/2018 | 9.70 | -0.36 | -1.29 | NA | Q4 2017 3/1/2018 | 8.90 | -0.35 | -1.23 | NA | Q3 2017 11/7/2017 | 7.60 | -0.29 | -1.17 | NA | Q2 2017 8/7/2017 | 7.35 | -0.29 | -1.17 | NA | Q1 2017 5/3/2017 | 6.95 | -0.30 | -1.13 | NA | Q4 2016 3/1/2017 | 5.35 | -0.29 | -1.14 | NA | Q3 2016 11/7/2016 | 5.10 | -0.29 | -1.17 | NA | Q2 2016 8/8/2016 | 3.96 | -0.25 | -1.24 | NA | Q1 2016 5/5/2016 | 3.36 | -0.31 | -1.34 | NA | Q4 2015 3/2/2016 | 3.81 | -0.32 | -1.37 | NA | Q3 2015 11/9/2015 | 5.53 | -0.36 | -1.39 | NA | Q2 2015 8/10/2015 | 6.06 | -0.35 | -1.34 | NA | Q1 2015 5/8/2015 | 7.10 | -0.34 | -1.41 | NA | Q4 2014 3/12/2015 | 6.86 | -0.34 | -1.45 | NA | Q3 2014 11/13/2014 | 8.98 | -0.31 | NA | NA | Q2 2014 8/13/2014 | 15.82 | -0.42 | NA | NA | Q1 2014 5/12/2014 | 16.63 | -0.38 | NA | NA |
|
Quotes delayed 20 minutes
|
On this page we presented the KIN Historical PE Ratio information for Kindred Biosciences' stock.
The average KIN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 1.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculationg the "E" value at each measurement period, the average KIN historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this KIN historical PE result, against the recent PE: when this page was posted on 8/27/2021, the most recent closing price for KIN had been 9.25, and the most recent quarterly earnings result, annualized, was 2.4. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent KIN PE on 8/27/2021 based on annualized quarterly EPS was 3.9. Based on KIN's history, that recent PE is elevated relative to the historical average, with the recent PE 143.8% higher than the historical average PE across our data set for Kindred Biosciences.
For self directed investors doing their due diligence on KIN or any other given stock, valuation analysis for KIN
can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis
as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.
That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate
Kindred Biosciences PE history or the past PE information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for KIN. Thanks for visiting, and the next
time you need to research KIN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your
go-to historical PE ratio research resource of choice.